Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021()

Metastatic triple-negative breast cancer (mTNBC) is associated with an aggressive disease course, and limited treatment options. The recent accelerated drug development in the space of mTNBC has been driven by a precision-medicine approach, with the potential to deliver more personalized treatments...

Descripción completa

Detalles Bibliográficos
Autores principales: Trapani, Dario, Curigliano, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097802/
https://www.ncbi.nlm.nih.gov/pubmed/34920925
http://dx.doi.org/10.1016/j.breast.2021.12.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097802/
https://www.ncbi.nlm.nih.gov/pubmed/34920925
http://dx.doi.org/10.1016/j.breast.2021.12.012

Ejemplares similares